17 10, 2024

ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of preclinical chronic hepatitis B data at AASLD 2024.

ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of pre-clinical chronic hepatitis B data at AASLD 2024. CONCORD, MA, 17 OCTOBER 2024 — ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to [...]

Read More
12 10, 2023

ClearB Therapeutics Announces First Patient Dosed in a Phase 1b First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B Infection

ClearB Therapeutics Announces First Patient Dosed in a Phase 1b First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B Infection October 12, 2023 07:00 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, [...]

Read More
15 06, 2022

ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022

ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 June 15, 2022 09:16 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, [...]

Read More
21 06, 2021

ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021

June 21, 2021 ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021 CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract [...]

Read More

ClearB is working to develop therapeutic vaccines designed to redirect patients’ immune systems toward functional cure of hepatitis B.

Our work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B.

ClearB Therapeutics © 
LinkedInEmail
We use cookies to optimise our service and personalise content for a better user experience. To find out more, please see our Privacy Policy. I understand